Journal:

Article Title: Involvement of CYP1A2 in mexiletine metabolism

doi: 10.1046/j.1365-2125.1998.00048.x

Figure Lengend Snippet: Effects of CYP inhibitors on mexiletine a) p-hydroxylase activity and b) 2-hydroxylase activity in human liver microsomes. The concentration of mexiletine was 20 μm. The ranges of concentration of furafylline (▵), ethoxyresorufin (▴) and quinidine (•) were 0.25–10 μm, and that of bufuralol (○) was 1–100 μm. Each data point represents the mean of duplicate determinations (HL 2).

Article Snippet: 7-Ethoxyresorufin and resorufin were from Sigma (St Louis, MO), furafylline was from Funakoshi (Tokyo, Japan).

Techniques: Activity Assay, Concentration Assay

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Article Title: In vitro metabolism of piperaquine is primarily mediated by CYP3A4

doi: 10.3109/00498254.2012.693972

Figure Lengend Snippet: The effect of isoform selective P450 inhibitors on piperaquine metabolism. The data is expressed as percent piperaquine remaining (mean ± SD of triplicate determinations) as a function of time following human liver microsome incubations in the presence of isoform selective P450 inhibitors. The starting concentration of piperaquine was 0.6 µM. The following concentrations of inhibitors were used: 1 µM ketoconazole (CYP3A4), 5 µM ticlopidine (CYP2C19), 20 µM furafylline (CYP1A2), 20 µM sulfaphenazole (2C9), and 25 µM quercetin (CYP2C8).

Article Snippet: Sulfaphenazole and furafylline were purchased from BD Biosciences (San Jose, CA).

Techniques: Concentration Assay